Rheumatic Disease Clinics of North America

Papers
(The median citation count of Rheumatic Disease Clinics of North America is 0. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)
ArticleCitations
Pediatric Rheumatology Comes of Age: Part II93
Lessons from Cardiac and Vascular Biopsies from Patients with and without Inflammatory Rheumatic Diseases69
Implementation Science in Pediatric Rheumatology: A Path to Health Equity49
Contents37
Copyright36
Kawasaki Disease and Multisystem Inflammatory Syndrome in Children28
Advancing Gastrointestinal Microbiota Research in Systemic Sclerosis27
Immune Checkpoint Inhibitor-induced Inflammatory Arthritis26
Molecular Pathways in the Pathogenesis of Systemic Juvenile Idiopathic Arthritis24
Osteoarthritis Treatment Guidelines from Six Professional Societies24
Copyright21
Forthcoming Issues21
Immune Checkpoint Inhibitor-induced Polymyalgia Rheumatica21
Exploring the Mucosal Immune Response in Axial Spondyloarthritis Through Immunoglobulin A-Coated Microbiota20
Impact of Non-steroidal Anti-inflammatory Drugs, Glucocorticoids, and Disease-Modifying Anti-Rheumatic Drugs on Cancer Response to Immune Checkpoint Inhibitor Therapy19
COPA Syndrome from Diagnosis to Treatment19
Contributors17
Taxonomy of Quality of Care Indicators16
Venous Thromboembolism in the Inflammatory Rheumatic Diseases16
Lessons Learned from the COVID-19 Pandemic in Rheumatology15
B Cells in Systemic Lupus Erythematosus14
Imaging Challenges and Developments in Large-vessel Vasculitis14
Newer Immunosuppressants for Rheumatologic Disease14
The Short and Long of COVID-1914
Contents14
T Cells in Systemic Lupus Erythematosus14
Vaccinations in Patients with Rheumatic Disease13
It Takes Oysters to Generate Pearls12
Contents12
Multisystem Inflammatory Syndrome in Children and Kawasaki Disease12
Pulmonary Hypertension Associated with Connective Tissue Disease11
Copyright11
Primary Cardiac Involvement in Systemic Sclerosis11
Expanding the Treatment Team11
The Utility of Laboratory Investigations for the Assessment and Management of Rheumatic Immune Related Adverse Events10
De novo Connective Tissue Disorders as Immune-related Adverse Events10
Uveitis in Children and Adolescents10
Rheumatology Pearls for the Primary Care Physician9
Clinically Relevant Biomarkers in Connective Tissue Disease-Associated Interstitial Lung Disease9
Scleroderma: Best Approaches to Patient Care9
Managing Immunosuppression in Vasculitis Patients in Times of Coronavirus Disease 20199
Mimickers of Immune Checkpoint Inhibitor-induced Inflammatory Arthritis8
Assessing Patient-Reported Outcomes in Pediatric Rheumatic Diseases8
COVID-19 and Rheumatology8
Systemic Lupus Erythematosus Classification and Diagnosis8
A Guide to Contemporary Clinical Practice Guidelines7
Preventative Care in Scleroderma7
Cardiac MRI in Rheumatic Disease7
Guideline Development and Implementation in Rheumatic Disease7
Charles L Christian7
Daniel J McCarty, MD: A Giant of Rheumatology7
Contributors7
Chronic Nonbacterial Osteomyelitis7
Heart Failure in Rheumatic Disease6
Imaging of the Major Salivary Glands in Rheumatic Disease6
Antinuclear Antibody Testing for the Diagnosis of Systemic Lupus Erythematosus6
Imaging of Pulmonary Manifestations of Connective Tissue Disease6
The Giants of Rheumatology at Johns Hopkins: Lawrence E Shulman, MD, PhD and Mary Betty Stevens, MD6
E Carwile LeRoy, MD6
Contributors6
Contents6
Copyright6
The Challenges of New Biologic Therapies in Pediatrics6
Copyright5
Cardiovascular Comorbidities in Inflammatory Rheumatic Diseases5
The Role of Psychology in Pediatric Rheumatic Diseases5
Forthcoming Issues5
Biomarkers in Childhood-Onset Systemic Lupus Erythematosus5
Cardiovascular Comorbidities in Inflammatory Rheumatic Diseases5
Therapeutic Advances in Eosinophilic Granulomatosis with Polyangiitis5
Contributors5
The Power of Systems Biology5
The Impact of Pediatric Rheumatic Diseases on Sexual Health, Family Planning, and Pregnancy5
Environmental Triggers for Rheumatic Disease: From “Why Did I Get This?” to “How Can We Prevent This?”5
Beyond Coronary Artery Disease5
Treatment Guidelines in Pediatric Rheumatic Diseases4
Copyright4
Updates in Systemic Sclerosis Treatment and Applicability to Pediatric Scleroderma4
Treatment Guidelines in Gout4
Role of Environment in Pediatric Rheumatic Diseases4
Pediatric Rheumatology Comes of Age: Part I4
Cardiovascular Health in Pediatric Rheumatologic Diseases4
Recommendations for the Use of Nonsteroidal Anti-inflammatory Drugs and Cardiovascular Disease Risk4
SARS-CoV-2 Infection and COVID-19 in Children4
CARRA4
Management and Cure of Gouty Arthritis4
Health Care Utilization4
Dual-Energy Computed Tomography Applications in Rheumatology4
Environmental Risk Factors for Osteoarthritis: The Impact on Individuals with Knee Joint Injury4
Genetic Defects in Early-Onset Inflammatory Bowel Disease4
Patient Engagement in Pediatric Rheumatology Research4
Contents4
Pediatric Rheumatic Disease in Lower to Middle-Income Countries4
Update on the Treatment of Giant Cell Arteritis and Polymyalgia Rheumatica3
Molecular Biomarkers and Clinical Predictors of Psoriatic Arthritis3
Interstitial Lung Disease3
Instrumental Substance Use Among Youth with Rheumatic Disease—A Biopsychosocial Model3
Systemic Lupus Erythematosus Outcome Measures for Systemic Lupus Erythematosus Clinical Trials3
Expanding IPEX: Inborn Errors of Regulatory T Cells3
Achieving Precision Medicine in Psoriatic Arthritis3
Interferons in Systemic Lupus Erythematosus3
Mental Health in Pediatric Rheumatology3
Technology to Assess and Treat Pain in Pediatric Rheumatology3
Imaging in Inflammatory Bowel Disease3
Forthcoming Issues3
The GRADE Method3
Pediatric Rheumatology Comes of Age: Part II3
Treatment Approaches to Granulomatosis with Polyangiitis and Microscopic Polyangiitis2
Imaging in Juvenile Idiopathic Arthritis2
Forthcoming Issues2
Lifestyle, Hormonal, and Metabolic Environmental Risks for Rheumatoid Arthritis2
J. Claude Bennett, MD2
Contributors2
Pediatric Rheumatology Comes of Age: Part I2
Systemic Diseases and Heart Block2
Forthcoming Issues2
Contributors2
COVID-19 in Pediatrics2
Training the Next Generation of Rheumatologists2
Precision Medicine2
Contributors2
Forthcoming Issues2
Nathan Zvaifler2
Gerald P Rodnan2
Targeting Environmental Risks to Prevent Rheumatic Disease2
Perioperative Management of Rheumatic Disease and Therapies2
Forthcoming Issues2
Early Sexual Health and Reproductive Implications in Pediatric Rheumatic Diseases2
Outcome Measures in Pediatric Rheumatic Disease2
Imaging in Rheumatology2
The Promises and Perils of Social Media for Pediatric Rheumatology2
Preface2
Rheumatic Complications of Immune Checkpoint Inhibitors1
Long COVID for the Rheumatologist1
Foreword1
Cardiovascular Disease in Large Vessel Vasculitis1
Vasculitis1
Recent Updates in Juvenile Spondyloarthritis1
Evidence for Biologic Drug Modifying Anti-Rheumatoid Drugs and Association with Cardiovascular Disease Risk Mitigation in Inflammatory Arthritis1
Axial Imaging in Spondyloarthritis1
Targeted Treatment of Diseases of Immune Dysregulation1
Foreword1
Novel Therapeutic Targets in the Management of Psoriatic Disease1
Transitioning to Adulthood with a Rheumatic Disease1
Treatment Guidelines in Vasculitis1
Treatment Update in Systemic Lupus Erythematous1
Foreword1
Juvenile Fibromyalgia1
The Giants Of Rheumatology1
Copyright1
Immune Checkpoint Inhibitor-induced Myositis1
Foreword1
Treatment of Inflammatory Arthritis in Systemic Sclerosis1
Multi-Organ System Screening, Care, and Patient Support in Systemic Sclerosis1
The Current and Future of Biomarkers of Immune Related Adverse Events1
Treatment of Vascular Complications in Systemic Sclerosis1
Forthcoming Issues1
Suspecting and Diagnosing the Patient with Spondyloarthritis and What to Expect from Therapy1
Contributors1
Highlights of Interdisciplinary Care in Rheumatology1
The Need for Classification Criteria of Immune Checkpoint Inhibitor-induced inflammatory Arthritis1
Scleroderma Skin0
Juvenile Localized Scleroderma0
Type I Interferonopathies0
The Role of Imaging in Diagnosis and Monitoring of Large Vessel Vasculitis0
Vascular, Soft Tissue, and Musculoskeletal Imaging in Systemic Sclerosis0
Review of Immunologic Manifestations of COVID-19 Infection and Vaccination0
Preventative Care in Scleroderma0
Pre-existing Autoimmune Diseases and Immune Checkpoint Inhibitors for Cancer Treatment: Considerations About Initiation, Flares, Immune-Related Adverse Events, and Cancer Progression0
Pediatric Rheumatology Comes of Age: Part II0
New Developments in Imaging in Crystalline Arthritis0
The Burden of Post-Acute Sequelae of Coronavirus Disease 2019 in Individuals with Rheumatic Diseases0
Innovative Trials and New Opportunities in SLE0
Systemic Autoinflammatory Diseases0
The Emerging Telehealth Landscape in Pediatric Rheumatology0
Suppressor of Cytokine Signaling 1 Haploinsufficiency0
Mental Health Considerations in Chronic Disease0
Combined Dermatology/Rheumatology Clinics for Management of Psoriatic Disease0
The Temporomandibular Joint in Juvenile Idiopathic Arthritis0
Interventions to Improve COVID-19 Vaccine Hesitancy0
Scleroderma: Best Approaches to Patient Care0
Rheumatic Immune-related Adverse Events0
Ear, Nose, and Throat Manifestations of Vasculitis and Other Systemic Autoimmune Diseases0
Imaging of Rheumatic Diseases Affecting the Lower Limb0
Lessons from Carl M. Pearson 1919 – 19810
Guideline Development and Implementation in Rheumatic Disease0
Eric Bywaters and Barbara Ansell0
Myocardial Involvement in Systemic Autoimmune Rheumatic Diseases0
Forthcoming Issues0
Newer Immunosuppressants for Rheumatologic Disease0
Considerations for Coronavirus Disease 2019 Vaccination Among B-Cell-Depleted Patients0
Best Approaches to the Care of Systemic Sclerosis Patients0
Managing Cardiovascular Risk in Patients with Rheumatic Disease0
Emerging Concepts in Immune Dysregulation0
Axial Psoriatic Arthritis0
Understanding the Spectrum of Immune Dysregulation Manifestations in Autoimmune Lymphoproliferative Syndrome and Autoimmune Lymphoproliferative Syndrome-like Disorders0
Highlights of Interdisciplinary Care in Rheumatology0
Emerging Concepts in Immune Dysregulation0
Forthcoming Issues0
Environmental Triggers for Rheumatic Diseases0
Hal Holman of Stanford0
How the American College of Rheumatology Develops Guidelines0
Patient Experience of Systemic Sclerosis–Related Calcinosis0
Lupus Cohorts0
Forthcoming Issues0
Naomi Rothfield, MD, MACR0
Vasculitis and Pregnancy0
New and Emerging Rheumatic Diseases0
Lessons on Telemedicine in Rheumatology0
John R. Ward, MD: Pioneer—Clinical Trials in Rheumatology0
Contents0
Environmental Risks for Systemic Sclerosis0
Pathogenesis and Treatment of Refractory Disease Courses in Systemic Juvenile Idiopathic Arthritis0
Central Nervous System Vasculitis0
Management of Pregnancy in Lupus0
Challenges in Developing Treatment Guidelines in Psoriatic Arthritis0
Copyright0
Environmental Risks for Spondyloarthropathies0
Contributors0
Contents0
Imaging Revolutions in Modern Rheumatology0
Contributors0
Juvenile Idiopathic Arthritis Treatment Updates0
Forthcoming Issues0
Environmental Risks for Inflammatory Myopathies0
Flares of Systemic Autoimmune Rheumatic Disease Following Coronavirus Disease 2019 Vaccination0
Forthcoming Issues0
The Future of Vasculitis0
Pediatric Rheumatology Comes of Age: Part I0
Rheumatoid Arthritis0
Gut and Joint Microbiomes0
Vasculitis Mimics and Other Related Conditions0
Abnormal Mitochondrial Physiology in the Pathogenesis of Systemic Lupus Erythematosus0
Cardiovascular Complications of Chronic Rheumatic Diseases0
Contents0
Contents0
Systemic Lupus Erythematosus Risk0
Lupus0
Copyright0
The Impact of Coronavirus Disease 2019 on Patients Living with Rheumatic Diseases0
Environmental Triggers for Rheumatic Diseases0
Foreword0
Giant Cell Arteritis and Polymyalgia Rheumatica0
Gastrointestinal Tract Considerations: Part II0
Isolated Aortitis0
Immunotherapy Toxicity Management in Clinical Practice0
Forthcoming Issues0
Rheumatology Pearls for the Primary Care Physician0
Copyright0
Lung Microbiome in Autoimmune-Associated Interstitial Lung Disease0
0.063075065612793